Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subconjunctival Bevacizumab for Recent-Onset Corneal Neovascularisation
2008-007984-17Phase 4Completed
- Sponsor
- Moorfields Eye Hospital
- Start
- Nov 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in corneal neovascularization (CNV) comparing Subconjunctival Avastin with Placebo (2 arms). Primary endpoint: Change in area of corneal neovascularisation. Started Nov 2010; status: completed.
02
Drugs
bevacizumab
03
Conditions
corneal neovascularization (CNV)
Beyond the preview
Go deeper on 2008-007984-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007984-17.